cnbc_topnews

Rudy Giuliani, former New York mayor and Trump lawyer, hospitalized in critical condition

rudy giuliani, 81, is hospitalized in florida in "critical but stable condition" as of sunday night, according to his spokesman ted goodman. no details on what caused it. goodman called him a fighter and asked for prayers.

on friday, giuliani hosted his show "america's mayor live" from palm beach, where he coughed and sounded raspy. "my voice is a little under the weather," he said. trump posted on truth social praising giuliani as a "true warrior" and repeating election denial claims.

giuliani was new york mayor from 1994 to 2001, led the city's 9/11 response, and ran for president in 2008. he was later indicted in georgia and arizona over efforts to overturn the 2020 election. he was found liable for defaming two georgia election workers and ordered to pay nearly $150 million. he was disbarred in new york in july 2024 and in washington, d.c. two months later.

source: cnbc_topnews
sentiment: -0.20 · impact: 0.30

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds